Idiopathic pulmonary fibrosis (IPF) is a lung disease similar to asbestosis. Both
diseases cause:
• the death of alveolar epithelial cells due to DNA damage
• dead cells to be replaced by inelastic, fibrous scar tissue.
Currently, there is no cure for asbestosis and no effective treatment to slow its progression. There is also no cure for IPF. However, the drugs nintedanib and pirfenidone can slow the formation of scar tissue and slow the progression of IPF.
In two separate clinical trials, doctors investigated the effect of nintedanib and pirfenidone on 263 IPF patients.
• 124 patients were treated with nintedanib. 7 of these patients had to stop treatment due to side effects.
• 139 patients were treated with pirfenidone. 14 of these patients had to stop treatment due to side effects.
The doctors recorded how many days each patient lived after treatment.
Figure 6 shows their results.
Suggest why neither clinical trial had a control group.